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INTRODUCTION
Hepatic encephalopathy (HE) has a large impact on the patient, caregivers, and health care team. 
From 2005 to 2009, there were 110,000 hospitalized patients in the United States.  Overt hepatic
encephalopathy (OHE) may occur in up to 50% of all cirrhotic patients.  In 2013, the American
Association for the Study of Liver Diseases (AASLD) in conjunction with the European Association
for the Study of the Liver (EASL) released a treatment guideline for the management of hepatic
encephalopathy.  In addition to developing the definition and classification, treatment approaches
were developed with a caveat that the evidence supporting treatment was not the most robust.
This review is of the recommendations from the guidelines, as well as a review of specific literature.
AASLD/EASL hepatic encephalopathy utilized the following score for determining the level of
evidence behind each recommendation (table 1).
Table 1. GRADE system for evidence
Grade Evidence
I Randomized, control trials
II-1 Controlled trials, without randomization
II-2 Cohort or case-control studies
II-3 Multiple time series, uncontrolled experiments
III Expert opinion or descriptive epidemiology
Evidence Description
High
quality
Further evidence unlikely to change the estimated effect A
Moderate Further research is likely to have important impact on our confidence in the estimation of
effect and may change the estimate
B
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Low
quality
Further research is likely to have important impact on our confidence in the estimation of
effect and is likely to change the estimate
C
Recommendation
Strong Factors influencing the quality of the recommendation include quality evidence, patient
important factors, and costs
1
Weak More uncertainity, variance in preference or values.  Recommendation with less certainity,
higher costs, or resource consumption.
2
HE has been defined as the brain dysfunction in patients with liver failure with or without
portosystemic shunting that results in neurological or psychological abnormalities.  Initiation of
therapy for the treatment of HE should begin, but identifying and treating the underlying
precipitating factor is paramount to successful treatment.  Therapies for treatment of hepatic
encephalopathy include nonabsorbable disaccharides (lactulose), rifaxamin, and other treatments.
Nonabsorbable Disaccharides
AASLD recommends that the first line of therapy is lactulose (GRADE II-1, B, 1) and lactulose use for
prevention of recurrent episodes (GRADE II-1, A, 1).   Lactulose produces reduction of ammonia
levels through acidification of the colon which results in conversion of ammonia to ammonium
which elicits a prebiotic effect.  In addition lactulose, lactitol, and polytethylene glycol (PEG) produce
a cathartic effect.  While the evidence supporting the use of lactulose is limited by the
methodological deficiencies, the decades of use and cost comparison have led to continued
recommendation of use.
Lactulose vs. PEG-3350
A recent article published in JAMA by Rahimi et al studied the use of PEG-3350 solution versus
lactulose in hepatic encephalopathy. It was hypothesized that catharsis of the gut would lead to
relief in OHE, which would make PEG-3350 superior to lactulose. Primary endpoint was decrease in
hepatic encephalopathy scoring algorithm (HESA) score from baseline (table 2).
Table 2. HESA Scoring System
Criteria for Scoring
Grade 4 Must include each of the following:
No eyes opening
No reaction to simple commands
No verbal response
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Grade 3 3 or more of the following:
Somnolence
Confusion
Disorientated to place
Bizarre behavior/anger/rage
Clonus/rigidity/nystagmus/Babinsky
No mental control*
Grade 2 Any 3 of the following:
Lethargy
Hyperactive reflexes
Loss of time
Inappropriate behavior
Slurred speech
Or any 2 of the following:
Slow responses*
Anxiety*
Amnesia*
Impaired simple computation*
Grade 1 Any 4 of the following:
Sleep disorder/impaired sleep
Tremor
Impaired complex computations*
Short attention span*
Impaired construction ability*
Euphoria or depression*
Grade 0 Does not meet any other grade criteria
*Symptoms assessed using neuropsychological measures
The study observed the use of either lactulose or PEG-3350 4-Liters in 50 patients. The authors
found that PEG-3350 was superior to reducing HESA scores over 24 hours. In the lactulose arm, 52%
of patients reached the primary endpoint compared to 91% of patients in the PEG-3350 group (p <
0.01). Additionally, the mean (± SD) HESA score change was greater with PEG-3350 treatment (1.5 ±
0.8) versus lactulose (1.5 ± 0.8) (p < 0.002), and median time to resolution of HE was shorter with
PEG-3350 (p = 0.01). Side-effects were comparable between groups with diarrhea being more
prevalent in the PEG-3350 arm and bloating being more common in lactulose. Electrolyte
abnormalities and dehydration were no significantly different between treatment arms, although
the study may have been underpowered to detect this.
There were many limitations to this study. First, there was limited blinding as it was impossible to
blind the PEG-3350 container. Additionally, it was a small, single-centered study. Even though the
study technically met power, the effect to lactulose may have been underestimated and a large
effect size for PEG-3350 was assumed. Regardless of these limitations, a large effect was observed
and PEG-3350 is as widely available and affordable as lactulose. Further studies on the use of PEG-
3350 for HE may be warranted.
Rifaximin
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The intestinal production of ammonia and its absorption is reduced due to the alteration in the
gastrointestinal microflora from the administration of rifaximin.  An additional benefit is the lack of
systemic side effects seen as rifaximin is not absorbed.  The AASLD guidelines recommend rifaximin
as an effective additional therapy for patient on lactulose to prevent the recurrence of episodes
(GRADE I, A, 1).
Lactulose vs. Rifaximin
The controversy of using rifaximin either in place of or in addition to lactulose has waged on
despite current practice guidelines that recommend lactulose as first-line treatment. Rifaximin
proved effective compared to placebo in 299 patients with recurrent encephalopathy (HE) who were
in remission. Rifaximin 550 mg twice daily did recue the risk of an episode of hepatic
encephalopathy (HR 0.42; 95% CI [0.250-0.64]) as well as the risk of hospitalization from hepatic
encephalopathy (HR 0.50; 95% CI [0.29 – 0.87]). Of note, over 90% of patients in each arm were on
baseline lactulose and upon sub-group analysis, those patients who were not using lactulose at
baseline had no significant differences in outcomes with rifaximin compared to placebo. Overall,
treatment was well tolerated and rifaximin had positive outcomes.
In one study by Leevy and Phillips, investigators sought to compare frequency and duration of
hospitalizations related to hepatic encephalopathy with rifaximin versus lactulose. Charts of 145
patients using lactulose 30mLs twice daily for ≥ 6 months or rifaximin 400mg three times daily for ≥
6 months were retrospectively reviewed. Less patients taking rifaximin were hospitalized during the
treatment period versus those taking lactulose, had shorter hospitalization time, and lower
hospitalization charges (p < 0.001 for all measures). Diarrhea, flatulence, and abdominal pain were
reported more in the lactulose group over rifaximin (p < 0.001). Of note, a low compliance rate
(defined as missing < 25% of doses) was noted in a large percentage of lactulose patients (31%)
versus rifaximin patients (92%) and was attributed to poor tolerability. Another limitation would be
the dosing strategies used. Many patients may require higher doses of lactulose (titrated to 3 to 4
loose stools per day) than twice daily. Additionally, recommended dosing for rifaximin in hepatic
encephalopathy ranges and is often 550mg twice daily instead of 400mg three times daily.
Probably the most common prescribing method is the use of rifaximin with lactulose. A study by
Sharma et al demonstrated this by comparing lactulose alone to lactulose plus rifaximin. This study
evaluated 120 patients with overt HE (>80% grade 3 or 4) who were randomized to receive either
lactulose alone or lactulose plus rifaximin. Baseline Child-Pugh was mainly Class B and C and Mean
MELD was 24.5 ± 4.2. Of these patients, 55 had experienced previous episodes of HE requiring
treatment, but no patients were refractory to treatments. There were more patients in the
combination therapy group that experienced reversal of HE symptoms within a 10 day period (76%
vs. 44% lactulose alone; p = 0.004). Patients treated with both lactulose and rifaximin also
experience shorter hospital stays (p = 0.01) and a decrease in mortality (p < 0.05; ARR 25.1%) with a
number needed to treat of 4. There were no notable differences in patients who died due to
gastrointestinal bleed or hepatorenal syndrome, but there were more deaths due to sepsis in
patients treated with lactulose alone. There were no serious side effects related to either treatment
arm reported with respect to abdominal pain or diarrhea. The authors hypothesized the different
mechanisms of action on gut flora resulted in synergistic action and increased efficacy of the two
treatments together.
1
4
5
6
5/30/2018 Overt Hepatic Encephalopathy: Pharmacotherapy Review
https://www.printfriendly.com/p/g/rY6Azf 5/6
Other studies have shown rifaximin is as effective and possibly superior than conventional therapies
such as lactulose and is well tolerated. However, there is still a lack of evidence to support rifaximin
as sole therapy for HE and the cost of rifaximin greatly exceeds the cost of lactulose. With the
available data and the updated guidelines from the AASLD, the recommendation is still lactulose as
first choice for the treatment of HE or for prevention of recurrent HE episodes after initial episode
and rifaximin as effective add-on therapy.
Other therapies
The guidelines currently address other therapies available for use including branch-chained amino
acids (BCAAs), L-ornithine L-aspartate (LOLA), Probiotics, Glutaminase inhibitors, neomycin,
metronidazole, albumin, or laxatives. The guidelines conclude BCAA’s, LOLA, neomycin, and
metronidazole may have a role for refractory patients who fail to respond to conventional therapy.
Other therapies lack evidence that show benefit and should not be recommended at this time.
(AASLD)
Summary and Recommendations
Overt hepatic encephalopathy remains a significant complication of cirrhosis. The updated AASLD
guidelines highlight the need for better controlled clinical treatments for effects of different forms
of HE and specific complications. There is also a lack of standardization between trials which makes
comparing treatments difficult. Future studies need to better assess effects of HE on individual and
societal costs, diagnostic tools, and therapeutic goals.
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